BCI-215

BCI-215 (BCI215) is a potent, tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor; restores defective MAPK activity caused by overexpression of DUSP1 and DUSP6 in mammalian cells; inhibits cell motility, causes apoptosis but not primary necrosis, and sensitizes cells to lymphokine-activated killer cell activity in MDA-MB-231 human breast cancer cells; induces rapid and sustained phosphorylation of ERK, p38 and JNK, also hyperactivates MKK4/SEK1; causes selective cancer cell cytotoxicity in part through non-redox-mediated activation of MAPK signaling.

References 1. Kaltenmeier CT, et al. J Pharmacol Exp Ther. 2017 Apr;361(1):39-50. View Related Products by Target Protein Phosphatase/PTP